Last reviewed 2026-04-20 · How we verify

Diodon (DIODONE)

Phase 2 active Small molecule

Diodon (generic name: DIODONE) is a diodone drug. It is currently in Phase 2 development.

Diodon works by blocking the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.

Diodon (DIODONE) is a small molecule drug in the diodone class, but specific details about its target, FDA approval status, and approved indications are unknown. As a diodone, it is likely a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting the enzyme cyclooxygenase (COX), which plays a key role in the production of prostaglandins that cause pain and inflammation. The commercial status of Diodon is also unclear, with no information available on whether it is patented or generic. Further research is needed to determine the safety considerations and potential side effects of Diodon. Overall, Diodon appears to be a relatively unknown drug with limited information available.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DIODONE
Drug class	diodone
Modality	Small molecule
Therapeutic area	Pain
Phase	Phase 2

Mechanism of action

Think of prostaglandins like messengers that tell your body to feel pain and become inflamed. When Diodon blocks these messengers, it helps to reduce pain and inflammation. This can be especially helpful for people with conditions like arthritis or other inflammatory diseases.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Diodon CI brief — competitive landscape report
Diodon updates RSS · CI watch RSS

Frequently asked questions about Diodon

What is Diodon?

Diodon (DIODONE) is a diodone drug.

How does Diodon work?

Diodon works by blocking the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.

What is the generic name of Diodon?

DIODONE is the generic (nonproprietary) name of Diodon.

What drug class is Diodon in?

Diodon belongs to the diodone class. See all diodone drugs at /class/diodone.

What development phase is Diodon in?

Diodon is in Phase 2.

Drug class: All diodone drugs
Therapeutic area: All drugs in Pain

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing